GD2 is known as ganglioside G2 or GRD2, which is used as a target for immunotherapy in patients with malignant melanoma and neuroblastoma. This protein is expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. Therefore, GD2 is associated with human neuroblastoma and melanoma.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
CAR-NK-1-M330-2 | Anti-GD2 scFv h(CD28) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28 | Lentiviral | NK cell | |
CAR-NK-1-M330-G | Anti-GD2 scFv h(FcεRIγ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-1-M330-Z | Anti-GD2 scFv h(CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M330-2Z | Anti-GD2 scFv h(CD28-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M330-4G | Anti-GD2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD4-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M330-4Z | Anti-GD2 scFv h(CD4-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD4-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M330-8Z | Anti-GD2 scFv h(CD8-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD8-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M330-BG | Anti-GD2 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M330-BZ | Anti-GD2 scFv h(41BB-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M330-CZ | Anti-GD2 scFv h(b2c-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-b2c-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M330-2BZ | Anti-GD2 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M330-2XZ | Anti-GD2 scFv h(CD28-OX40-CD3ζ) CARNK, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-OX40-CD3ζ | Lentiviral | NK cell | |
CAR-T-1-M326-2 | Anti-GD2 scFv h(CD28) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28 | Lentiviral | T cell | |
CAR-T-1-M326-G | Anti-GD2 scFv h(FcεRIγ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-FcεRIγ | Lentiviral | T cell | |
CAR-T-1-M326-Z | Anti-GD2 scFv h(CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M326-2Z | Anti-GD2 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M326-4G | Anti-GD2 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-M326-4Z | Anti-GD2 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD4-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M326-8Z | Anti-GD2 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD8-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M326-BG | Anti-GD2 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-M326-BZ | Anti-GD2 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-2-M326-CZ | Anti-GD2 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-b2c-CD3ζ | Lentiviral | T cell | |
CAR-T-3-M326-2BZ | Anti-GD2 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-3-M326-2XZ | Anti-GD2 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | ch14.18 | Chimeric | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |
CAR-LC007 | Anti-GD2 (huK666) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | huK666 | Human | scFv-CD28-CD3ζ | Retroviral | T cell | |
CAR-LC008 | Anti-GD2 (14g2a) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 14g2a | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
CAR-LC380 | Anti-GD2 h(CD28-CD3ζ,iCasp-9) Self-destruct CAR, pCDCAR1 | Human | Mouse | scFv-CD28-CD3ζ | Retroviral | NK cell | ||
CAR-MZ003 | Anti-GD2 scFv h(DAP10) CAR, pCDCAR1 | Human | Human | scFv-DAP10 | Retroviral | T cell | ||
CAR-MZ021 | Anti-GD2 scFv h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | Human | scFv-CD28-OX40-CD3ζ | Retroviral | T cell | ||
CAR-MZ044 | Anti-GD2 (14g2a) h(CD3ζ) CAR, pCDCAR1 | Human | 14g2a | Mouse | scFv-CD3ζ | Retroviral | T cell | |
CAR-MZ046 | Anti-GD2 (14g2a) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 14g2a | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | |
CAR-MZ047 | Anti-GD2 (14g2a) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 14g2a | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | |
CAR-MZ054 | Anti-GD2 (Dinutuximab) scFv h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Dinutuximab | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-MZ173 | Anti-GD2 (Clone 126) h(CD3ζ) CAR, pCDCAR1 | Human | Clone 126 | Mouse | scFv-CD3ζ | Retroviral | T cell | |
CAR-MZ174 | Anti-GD2 (Clone 126) h(CD28-CD3ζ) CAR, Pcdcar1 | Human | Clone 126 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
CAR-MZ175 | Anti-GD2 (Clone 126) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Clone 126 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | |
CAR-YF108 | Anti-GD2 (CBL-YF036) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF036 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-YF109 | Anti-GD2 (CBL-YF036) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBL-YF036 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-YF211 | Anti-GD2 (hKM666) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | hKM666 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-YF212 | Anti-GD2 (hKM666) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hKM666 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE